Biotech company Editas Medicine is planning to start human trials to genetically edit genes and reverse blindness.
Editas Medicine, which is based in the US, said it plans to become the first lab in the
world to ‘genetically edit’ the DNA of patients suffering from a genetic condition – in this case the blinding disorder ‘leber congenital amaurosis’.
The disorder prevents normal function of the retina; the light-sensitive layer of cells at the back of the eye. It appears at birth or in the first months of life and eventually sufferers can go completely blind.
Katrine Bosley, the chief executive of Editas Medicine, told a conference in the US that the company hopes to start trialling the technology on blind patients in 2017.
Source: telegraph.co.uk
No comments:
Post a Comment